Oncolytics Biotech (ONCY) Common Equity (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Common Equity for 18 consecutive years, with -$6.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 266.72% year-over-year to -$6.2 million in Q2 2026; TTM through Jun 2026 was -$6.2 million, a 266.72% decrease from a year earlier, with the FY2025 full-year figure at -$3.8 million, down 215.19% from the prior year.
• Common Equity was -$6.2 million for Q2 2026 at Oncolytics Biotech, down from -$3.8 million in the prior quarter.
• Over five years, Common Equity peaked at $27.6 million in Q1 2022 and troughed at -$6.2 million in Q2 2026.
• A 5-year average of $12.4 million and a median of $16.6 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity increased 3.7% in 2023 and slumped 266.72% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $19.5 million in 2022, then rose by 3.7% to $20.2 million in 2023, then slumped by 78.85% to $4.3 million in 2024, then sank by 188.7% to -$3.8 million in 2025, then slumped by 62.33% to -$6.2 million in 2026.
• The last three Common Equity figures came in at -$6.2 million (Q2 2026), -$3.8 million (Q4 2025), and $83563.0 (Q3 2025), per Business Quant data.